TABLE 2.
In vitro activities of eravacycline, tedizolid, norvancomycin, nemonoxacin, and comparative agents against Enterococcus species isolates
| Organism(s) (no. of isolates) | Antimicrobial | Breakpoint(s) | MIC (mg/L) |
% R | % S | |||
|---|---|---|---|---|---|---|---|---|
| Range | 50% | 90% | Mode | |||||
| E. faecalis (n = 567) | Eravacycline (FDA) | S ≤ 0.06 | ≤0.015 to 1 | 0.03 | 0.06 | 0.03 | 3a | 97 |
| Eravacycline (EUCAST) | S ≤ 0.125, R > 0.125 | ≤0.015 to 1 | 0.03 | 0.06 | 0.03 | 0.5 | 99.5 | |
| Tigecycline | S ≤ 0.25 | ≤0.06 to 2 | 0.125 | 0.25 | 0.125 | 1.4a | 98.6 | |
| Tedizolid | S ≤ 0.5 | ≤0.06 to >8 | 0.5 | 1 | 0.5 | 12.7a | 87.3 | |
| Linezolid | S ≤ 2, R ≥ 8 | 0.125 to >8 | 2 | 8 | 2 | 11.6 | 84.7 | |
| Vancomycin | S ≤ 4, R ≥ 32 | ≤0.125 to 4 | 1 | 2 | 1 | 0 | 100 | |
| Nemonoxacin | NA | ≤0.015 to >32 | 0.25 | 4 | 0.25 | NA | NA | |
| Levofloxacin | S ≤ 2, R ≥ 8 | ≤0.25 to >32 | 2 | 32 | 2 | 28.7 | 68.4 | |
| Ceftaroline | NA | ≤0.25 to >32 | 2 | 4 | 2 | NA | NA | |
| Ampicillin | S ≤ 8, R ≥ 16 | ≤1 to >64 | ≤1 | 2 | ≤1 | 1.8 | 98.2 | |
| Penicillin | S ≤ 8, R ≥ 16 | 0.5 to >8 | 2 | 4 | 2 | 4.4 | 95.6 | |
| Gentamicin (high level) | S ≤ 500, R ≥ 1,000 | ≤500 to >500 | ≤500 | >500 | ≤500 | 28.2 | 71.8 | |
| Nitrofurantoin | S ≤ 32, R ≥ 128 | 4 to >256 | 16 | 16 | 16 | 0.7 | 98.8 | |
| E. faecium (n = 501) | Eravacycline (FDA) | S ≤ 0.06 | ≤0.015 to 2 | 0.03 | 0.125 | 0.03 | 11.8a | 88.2 |
| Eravacycline (EUCAST) | S ≤ 0.125, R > 0.125 | ≤0.015 to 2 | 0.03 | 0.125 | 0.03 | 5.6 | 94.4 | |
| Tigecycline | S ≤ 0.25, R > 0.25 | ≤0.06 to >4 | ≤0.06 | 0.125 | ≤0.06 | 3.2 | 96.8 | |
| Tedizolid | S ≤ 0.5 | ≤0.06 to 8 | 0.5 | 0.5 | 0.5 | 2.4a | 97.6 | |
| Linezolid | S ≤ 2, R ≥ 8 | 0.5 to >8 | 2 | 2 | 2 | 1.8 | 93.4 | |
| Vancomycin | S ≤ 4, R ≥ 32 | 0.25 to >8 | 1 | 2 | 1 | 0 | 94 | |
| Norvancomycin | NA | 0.125 to >32 | 0.5 | 2 | 0.5 | |||
| Nemonoxacin | NA | ≤0.015 to >32 | 8 | 32 | 8 | NA | NA | |
| Levofloxacin | S ≤ 2, R ≥ 8 | ≤0.25 to >32 | >32 | >32 | >32 | 84 | 8.4 | |
| Ampicillin | S ≤ 8, R ≥ 16 | ≤1 to >64 | >64 | >64 | >64 | 85.6 | 14.4 | |
| Gentamicin (high level) | S ≤ 500, R ≥ 1,000 | ≤500 to >500 | ≤500 | >500 | ≤500 | 48.7 | 51.3 | |
| Nitrofurantoin | S ≤ 32, R ≥ 128 | 4 to 256 | 64 | 128 | 64 | 20.2 | 36.3 | |
| Vancomycin-resistant E. faecium (n = 30) | Eravacycline (FDA) | S ≤ 0.06 | ≤0.015 to 2 | 0.03 | 0.125 | 0.03 | 23.3a | 76.7 |
| Eravacycline (EUCAST) | S ≤ 0.125, R > 0.125 | ≤0.015 to 2 | 0.03 | 0.125 | 0.03 | 10.0 | 90.0 | |
| Tigecycline | S ≤ 0.25, R > 0.25 | ≤0.06 to >4 | ≤0.06 | 1 | ≤0.06 | 13.3 | 86.7 | |
| Tedizolid | S ≤ 0.5 | ≤0.06 to 0.5 | 0.25 | 0.5 | 0.5 | 0a | 100 | |
| Linezolid | S ≤ 2, R ≥ 8 | 0.5 to 4 | 2 | 2 | 2 | 0 | 93.3 | |
| Vancomycin | S ≤ 4, R ≥ 32 | 8 to >8 | >8 | >8 | >8 | 0 | 0 | |
| Norvancomycin | NA | 8 to >32 | >32 | >32 | >32 | |||
| Nemonoxacin | NA | 0.25 to 32 | 4 | 16 | 4 | NA | NA | |
| Levofloxacin | S ≤ 2, R ≥ 8 | 1 to >32 | >32 | >32 | >32 | 93.3 | 6.7 | |
| Ampicillin | S ≤ 8, R ≥ 16 | ≤1 to >64 | >64 | >64 | >64 | 93.3 | 6.7 | |
| Gentamicin (high level) | S ≤ 500, R ≥ 1,000 | ≤500 to >500 | >500 | >500 | >500 | 53.3 | 46.7 | |
| Nitrofurantoin | S ≤ 32, R ≥ 128 | 16 to 128 | 64 | 128 | 64 | 23.3 | 33.3 | |
| Vancomycin-susceptible E. faecium (n = 471) | Eravacycline (FDA) | S ≤ 0.06 | ≤0.015 to 2 | 0.03 | 0.125 | 0.03 | 11a | 89 |
| Eravacycline (EUCAST) | S ≤ 0.125, R > 0.125 | ≤0.015 to 2 | 0.03 | 0.125 | 0.03 | 5.3 | 94.7 | |
| Tigecycline | S ≤ 0.25, R > 0.25 | ≤0.06 to >4 | ≤0.06 | 0.125 | ≤0.06 | 2.5 | 97.5 | |
| Tedizolid | S ≤ 0.5 | 0.125 to 8 | 0.5 | 0.5 | 0.5 | 2.5a | 97.5 | |
| Linezolid | S ≤ 2, R ≥ 8 | 0.5 to >8 | 2 | 2 | 2 | 1.9 | 93.4 | |
| Vancomycin | S ≤ 4, R ≥ 32 | 0.25 to 4 | 1 | 2 | 1 | 0 | 100 | |
| Norvancomycin | NA | 0.5 | 1 | 0.5 | ||||
| Nemonoxacin | NA | ≤0.015 to >32 | 8 | 32 | 8 | NA | NA | |
| Levofloxacin | S ≤ 2, R ≥ 8 | ≤0.25 to >32 | >32 | >32 | >32 | 83.4 | 8.5 | |
| Ampicillin | S ≤ 8, R ≥ 16 | ≤1 to >64 | >64 | >64 | >64 | 85.1 | 14.9 | |
| Gentamicin (high level) | S ≤ 500, R ≥ 1,000 | ≤500 to >500 | ≤500 | >500 | ≤500 | 48.4 | 51.6 | |
| Nitrofurantoin | S ≤ 32, R ≥ 128 | 4 to 256 | 64 | 128 | 64 | 20 | 36.5 | |
a
Nonsusceptible rate for eravacycline, tigecycline, and tedizolid.